Alumis Inc. announced positive Phase 3 results for envudeucitinib, an oral TYK2 inhibitor, demonstrating rapid and durable improvements in moderate-to-severe plaque psoriasis, including scalp clearance, itch relief, and quality of life. The ONWARD program showed a 54% complete skin clearance rate at 48 weeks, the highest among oral therapies. Patients switching from placebo or apremilast achieved similar benefits to continuous treatment. Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the fourth quarter of 2026, aiming to offer a leading oral treatment option for psoriasis.
Alumis' new Phase 3 data on envudeucitinib shows a 54% complete skin clearance rate at 48 weeks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 09, 2026 14:41 WIB: Among 128 priced US health stocks, 62 rose and 62 fell. Notable movers include DFTX at USD 34.01 with 0% Sell / 100% Buy order activity, CTXR at USD 0.49 with 98% Sell / 2% Buy, and CAH at USD 238.84 with 0% Sell / 100% Buy.
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
Investec Bank Plc, acting as joint broker for SThree Plc, disclosed share transactions on October 29, 2026. The bank purchased and sold 49,799 ordinary shares of SThree Plc at prices ranging between 297.5 and 306.5 per share. No derivative or option ...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its share dealings on October 29, 2026. The bank purchased 218,193 ordinary shares at prices between 1091 and 1094 pence per share and sold 160,410 shares at prices bet...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share dealings on October 29, 2026. The bank purchased 10,640 ordinary shares at a price of 282.75 per share and sold 98 shares at 283 each. ...
